IP Library › Granted Patent US 10,420,963
Granted Patent B2
US 10,420,963 · App. 14/715,894 · Granted Sep 24, 2019

Non-irritating, non-blurring ophthalmic sunscreen

Inventor: A. Ebbie Soroudi (Los Angeles, CA)
Assignee: A. Ebbie Soroudi, M.D., M.S., A Professional Medical Corporation
A61Q17/04A61K8/0241A61K8/06A61K8/27A61K8/29A61K8/37A61K8/466A61Q19/00A61K2800/26A61K2800/412
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,420,963
App. No.
14/715,894
Granted
Sep 24, 2019
Kind
B2
Abstract

A non-irritation, non-blurring ophthalmic sunscreen composition contains a liquid vehicle base, such as an artificial tear formulation or an ophthalmic suspension or ointment. The composition includes at least one inorganic and/or at least one organic active ingredient. The inorganic active ingredients may include, but not be limited to zinc oxide, titanium dioxide, iron oxide, zirconium oxide, and cerium oxide. The organic active ingredients may include, but not be limited to dioxybenzone, octinoxate, octisalate, homosalate, avobenzone, octocrylene, para-aminobenzoic acid, cinoxate, methyl anthranilate, octocrylene, padimate O, ensulizole, sulisobenzone, trolamine salicylate, and ecamsule.

Claims (21)

1. An ophthalmic sunscreen solution, consisting of an inactive liquid vehicle base and an active sunscreen component, wherein the active sunscreen component consists of 0.25 percent to 15 percent by weight of an inorganic active ingredient selected from the group consisting of titanium dioxide, zinc oxide, iron oxide, zirconium oxide, cerium oxide and mixtures thereof; and

0.25 percent to 15 percent by weight of an organic active ingredient selected from the group consisting of dioxybenzone, octisalate, homosalate, avobenzone, octocrylene, para-aminobenzoic acid, cinoxate, methyl anthranilate, octocrylene, 2-ethylhexyl 4-(dimethylamino)benzoate, ensulizole, sulisobenzone, trolamine salicylate and ecamsule;

wherein the inactive liquid base is an ophthalmic artificial tear formulation.

2. The solution of claim 1 , wherein the inactive liquid vehicle base comprises an emulsifier.

3. The solution of claim 2 , wherein the emulsifier is selected from the group consisting of a silicone-based emulsifier, a polyethylene glycol emulsifier, a polysiloxane emulsifier, a glyscoside emulsifier, an acrylic-based emulsifier and combinations thereof.

4. The solution of claim 1 , wherein the inactive liquid vehicle base comprises an emollient.

5. The solution of claim 4 , wherein the emollient is selected from the group consisting of aloe extracts, oleaginous esters, ethers and combinations thereof.

6. The solution of claim 1 , wherein the inactive liquid vehicle base comprises a chelating agent.

7. The solution of claim 1 , wherein the ophthalmic sunscreen solution is in the form of an eye drop, a suspension, an emulsion, or an ointment.

8. An ophthalmic sunscreen solution, consisting of:

an inorganic active ingredient comprising 0.25 percent to 15 percent by weight;

wherein the inorganic active ingredient is selected from the group consisting of titanium dioxide, zinc oxide, iron oxide, zirconium oxide, cerium oxide and mixtures thereof;

wherein the inorganic active ingredient is in micronized form or nanoparticle form;

an organic active ingredient comprising 0.25 percent to 15 percent by weight;

wherein the organic active ingredient is selected from the group consisting of dioxybenzone, octisalate, homosalate, avobenzone, octocrylene, para-aminobenzoic acid, cinoxate, methyl anthranilate, octocrylene, 2-ethylhexyl 4-(dimethylamino)benzoate, ensulizole, sulisobenzone, trolamine salicylate and ecamsule; and

a liquid vehicle base;

wherein the liquid vehicle base is an ophthalmic artificial tear formulation;

wherein the ophthalmic sunscreen solution is in the form of an eye drop, a suspension, an emulsion, or an ointment.

9. The solution of claim 8 , wherein the liquid vehicle base comprises an emulsifier, wherein the emulsifier is selected from the group consisting of a silicone-based emulsifier, a polyethylene glycol emulsifier, a polysiloxane emulsifier, a glyscoside emulsifier, an acrylic-based emulsifier and combinations thereof.

10. The solution of claim 8 , wherein the liquid vehicle base comprises an emollient, wherein the emollient is selected from the group consisting of aloe extracts, oleaginous esters, ethers and combinations thereof.

11. The solution of claim 8 , wherein the liquid vehicle base comprises a preservative, a chelating agent, an antioxidant, an ophthalmic lubricant, an ophthalmic astringent or ecamsule.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2018
From: SOROUDI, A. EBBIE
To: A. EBBIE SOROUDI, M.D., M.S., A PROFESSIONAL MEDICAL CORPORATION
Reel/Frame 047345/0214 →
Continuity (2)
Provisional Application 62000071 · May 19, 2014
Related Publication 20150328098A1 · Nov 19, 2015